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Clinical practice guidelines (CPGs) have been published by the American College of Emergency 
Physicians (ACEP) since 1990 to advance the delivery of emergency medical care. These guidelines have 
raised controversy, and recent research shows that they are largely based on lower classes of evidence and 
expert opinion despite Institute of Medicine recommendations. The rigor of development and overall 
quality of these guidelines have not yet been assessed. Thus, we performed a systematic review and meta-
analysis to evaluate the quality of ACEP Clinical Policies using a recognized, validated appraisal 
instrument: Appraisal of Guideline for Research & Evaluation (AGREE II).  
The AGREE II instrument contains 23 appraisal items (scored on a 1 - 7 scale) in six quality domains and 
two overall assessments. The domains are Scope and Purpose, Stakeholder Involvement, Rigor of 
Development, Clarity of Presentation, Applicability, and Editorial Independence. Appraisals were 
performed independently and in random order by five trained appraisers. Primary outcomes were AGREE 
II ratings for each item, domain, and Overall Assessment. Domain and Overall Assessment ratings were 
standardized for analyses. Secondary analyses examined associations between AGREE II ratings and date 
of publication, strength of underlying evidence, and strength of recommendations. Additional analysis 
examined relationships between domain and Overall Assessment ratings.  
Twenty guidelines published from October 2008 to November 2017 were included. Of the six domains, 
Scope and Purpose scored highest and varied least (mean 90%, coefficient of variation (CV) 0.03), while 
Applicability scored lowest and varied most (mean 35%, CV 0.16). The four remaining domains had mean 
scores of 53% - 78% and CVs of 0.3 - 0.14. The mean Overall Assessment rating was 69% (CV 0.13) and 
was not associated with CPG publication date, strength of underlying evidence, or strength of 
recommendations. Statistically significant relationships were found between Overall Assessment ratings 
and two domains (Rigor of Development and Clarity of Presentation). 
Based on validated criteria, ACEP Clinical Policies have identifiable areas of strength and weakness. The 
overall CPG quality did not improve over time and is not explained by the quality of underlying evidence. 
ACEP Clinical Policies can be improved by including patient representation in the guideline development 
process and addressing factors that influence the application of these guidelines in clinical practice. 
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Introduction 
 
Background 
The explosion of medical literature in recent decades has provided increased 
access to evidence that can improve health care delivery, yet the volume of available 
resources can be overwhelming, the quality of the literature uncertain, and the 
consistency of information incongruous (1-3). Particularly in an era of digitized and 
electronic resources and libraries, it is possible to quickly disseminate vast quantities of 
information without standardized organization or curation of that content, thereby 
limiting translation into practice. Indeed, the Institute of Medicine’s (IOM) 2001 report 
“Crossing the Quality Chasm: A New Health System for the 21st Century” identified 
significant gaps between best-available evidence and medical practice (4).  
In an effort to close these gaps, clinical practice guidelines (CPGs) were 
developed to provide synthesized and critically appraised evidence to enhance clinician 
and patient decision-making.  CPGs aim to translate the complexity of scientific research 
findings into clinical recommendations and advance the quality of health care delivery 
through acceleration of knowledge translation, promotion of cost-effective practices, and 
reduction of practice variation (5). Further, CPGs can influence the development of 
educational programs, quality measures, and research agendas (6). 
Literature review 
In the past three decades, there has been a notable increase in the publication and 
use of CPGs among various medical specialty societies, health care institutions, and 
governmental bodies (5, 7). In 1989, there were an estimated 700 available guidelines, 
and, in 2017, there are over 6,400 guidelines from 79 countries listed in the Guidelines 
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International Network database (1, 8). This increase in the number of guidelines, however, 
has raised concern about the lack of standardization in the development process and 
information presentation.  Studies have shown that the recommendations provided in 
various CPGs can be conflicting (9, 10) and the information can be invalid, unreliable, or 
irrelevant to clinical practice (3, 11). Further, low quality CPGs have the potential to 
undermine the credibility of more valid guidelines and lead to patient harm if incorrect 
recommendations were implemented into practice (3, 9, 10). A prior review on the 
quality of guidelines produced in the 1990s showed that, out of 431 CPGs, 67% did not 
describe the individuals involved with guideline development, 88% did not report how 
evidence was identified, and 82% did not indicate the strength of recommendations (3, 
11). 
Concerns about the low quality and high variability of CPGs motivated the 
development of several initiatives to formalize methods for guideline appraisal. Most 
notably is the Appraisal of Guidelines for Research and Evaluation (AGREE) 
Collaboration, established in 1998 by an international group of researchers from 13 
countries (12). In 2003, this group developed the original AGREE instrument, which 
provided a systematic framework for assessing the methodological rigor, transparency of 
development, and quality of reporting in CPGs. The AGREE instrument has been 
translated into numerous languages, is the only appraisal tool that has been validated 
internationally, and has been formally endorsed by several organizations such as the 
World Health Organization Advisory Committee on Health Research (3, 12, 13). The 
instrument underwent revision in 2010, and the new AGREE II instrument has since been 
cited in over 650 publications (14). 
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Shortly after the release of the AGREE II instrument, the IOM also published its 
own report aimed to outline objective, scientifically valid, and consistent approaches to 
developing practice guidelines (5, 16). This 2011 report, “Clinical Practice Guidelines 
We Can Trust,” provided eight standards of guideline trustworthiness that are similar in 
content and structure to the AGREE II criteria (5, 12, 16, 17). Both the AGREE II 
instrument and IOM’s standards of trustworthiness have been widely applied in efforts to 
advance the quality and appropriate utilization of clinical practice guidelines (17- 27). 
Among the many medical specialties promulgating CPGs is emergency medicine.  
Given the broad nature of emergency medical care, policies outlining standardized 
approaches can have substantial effect on patient outcomes by promoting evidence-based 
acute diagnostics and treatments, reducing practice variation, and limiting unnecessary 
costs and interventions. Emergency physicians have also identified CPGs as essential to 
providing synthesized, curated content and reassurance of legal protection (28, 29). 
Guidelines specifically for emergency medical care were first published by the American 
College of Emergency Physicians (ACEP) in 1990. The first guideline focused on non-
traumatic chest pain and presented a general approach to undifferentiated disease, 
focusing on key aspects of the history and physical exam (1). Since then, the ACEP 
Clinical Policies Committee was formed and a formal methodology was adopted in 
parallel with the growing popularity and prominence of evidence-based medicine. Since 
1998, ACEP has been publishing evidence-based, peer-reviewed guidelines structured to 
answer specific, clinically relevant questions considered to be of high frequency or high 
risk in emergency medicine (1, 2). 
Despite the positive effect that ACEP Clinical Policies have on the delivery of 
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emergency care (19), they have also been a target for scrutiny and a source of controversy. 
ACEP’s 2013 Clinical Policy on intravenous tissue plasminogen activator (tPA) use in 
acute ischemic stroke was met with skepticism by emergency physicians who felt that the 
recommendations lacked both adequate supporting evidence and consideration of the 
adverse outcomes of treatment (17, 28). Three out of eight panelists who developed this 
Clinical Policy disclosed relevant industry relationships, yet seven had affiliations with 
the Foundation for Education and Research in Neurological Emergencies, which received 
all of its donations from drug companies, including alteplase manufacturer, Genentech 
(17). This concern about industry influence resulted in not only revision of the 
guideline’s recommendations but also substantial reevaluation of ACEP’s Clinical Policy 
development process, rating methodology, and management of conflicts of interest (30). 
This methodological update was applied to the revised version of the Clinical Policy on 
tPA use, published in September 2015, and all policies published since. Another recent 
analysis of ACEP’s Clinical Policies revealed that the majority of clinical 
recommendations are based on lower classes of evidence or expert opinion as opposed to 
higher classes of evidence such as controlled clinical trials (6). To date, there has been no 
formal appraisal of ACEP’s Clinical Policies to evaluate their quality based on validated 
criteria. 
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Statement of Purpose 
 
Accordingly, we sought to assess the methodological rigor, transparency of 
development, and overall quality of current ACEP Clinical Policies using the AGREE II 
appraisal instrument. Secondarily, we sought to examine whether AGREE II ratings 
reflected improvement in Clinical Policies’ quality over time and, specifically, after 
ACEP methodological updates in 2015. We also evaluated whether certain aspects of 
CPG quality were related to the CPG’s overall quality assessment. Finally, we examined 
whether there were associations between AGREE II ratings and the strength of 
underlying evidence or recommendations in these CPGs.  
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Methods 
 
Overview of thesis responsibilities 
 AZ and AV established the purpose and scope of this thesis project. AZ 
developed the draft data collection tool and study protocol with supervision by AV. AZ 
utilized the AGREE II instrument to assess all ACEP Clinical Policies in this study. To 
meet recommendations made by AGREE II developers, the project was expanded to 
include additional review by emergency medicine residents (TT, GS, KC, MJ). AZ, AV, 
and CR analyzed and interpreted the data.  AZ primarily drafted the manuscript with 
critical review and revision by CR and AV.  
 
Study design 
Systematic review of American College of Emergency Physicians Clinical 
Policies using the AGREE II appraisal instrument (32, 33). 
Selection of clinical practice guidelines 
We included all American College of Emergency Physician (ACEP) Clinical 
Policies listed as “current” as of May 24, 2017, from the ACEP Clinical & Practice 
Management website, http://www.acep.org/clinicalpolicies/. During data collection, one 
Clinical Policy was replaced with a revised version ("Emergency Department 
Management of Patients Needing Reperfusion Therapy for an ST-Segment Elevation 
Acute Myocardial Infarction”) and thus our study included the revised policy and 
excluded the prior version. Also, after data collection, one Clinical Policy ("Critical 
Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency 
Department with Syncope”) was removed from the “current” list but remained in this 
study, as it was current at the time of initial guideline selection. Each Clinical Policy is 
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comprised of a peer-reviewed manuscript with evidence-based recommendations aimed 
to guide clinical decision-making. All Clinical Policies are authored by ACEP and follow 
the ACEP Clinical Policy development process, which includes expert review from 
medical specialists and societies relevant to the policy topic. These outside participants’ 
affiliations are noted in each Clinical Policy, and their involvement does not imply 
endorsement of the policy. ACEP Clinical Policies are specific to emergency care in the 
United States, are regularly published and maintained, and are sponsored by ACEP (6). 
While other professional organizations publish guidelines for, or relevant to, emergency 
care, few other groups have a regular process or a committee responsible for guideline 
maintenance. This study did not include clinical practice guidelines either published by 
other professional organizations in emergency medicine or primarily authored by other 
organizations and co-signed or endorsed by ACEP. 
Data abstraction  
 The AGREE II instrument 
The data were abstracted using the electronic web tool created by the AGREE II 
developers, available at http://www.agreetrust.org/. This instrument consists of 23 key 
items organized within six quality domains and two additional global assessments. Each 
item is rated on a Likert scale between 1 (strongly disagree) and 7 (strongly agree). Each 
domain captures a unique dimension of guideline quality, specifically Scope and Purpose, 
Stakeholder Involvement, Rigor of Development, Clarity of Presentation, Applicability, 
and Editorial Independence. 
Scope and Purpose is concerned with the overall aim of the guideline, the specific 
health questions, and the target population.  
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Stakeholder Involvement focuses on the extent to which the guideline 
development group includes individuals from all relevant professional groups, represents 
the views of its intended users, and clearly defines its target population.  
Rigor of Development relates to the process utilized to gather and synthesize the 
evidence, the methods utilized to formulate the recommendations, and the criteria used to 
update them. Specifically, the items in this domain evaluate whether systematic methods 
were used to search for evidence, criteria for selecting the evidence are clearly described, 
the strengths and limitations of the body of evidence are identified, the methods for 
formulating the recommendations are clear, the risks and benefits have been considered, 
there is an explicit link between the recommendations and the supporting evidence, the 
guideline has been externally reviewed by experts prior to its publication, and a 
procedure for updating the guideline is provided.  
Clarity of Presentation addresses the language, structure, and format of the 
guideline, specifically whether the recommendations are specific and unambiguous, other 
options for management are presented, and key recommendations are easily identifiable.  
Applicability pertains to factors affecting guideline implementation, strategies to 
improve uptake, and resource implications of applying the recommendations in practice. 
These items evaluate whether the guideline describes facilitators and barriers to its 
application, advice or tools on how the recommendations can be put into practice, 
potential resource implications of applying the recommendation, and monitoring and/or 
auditing criteria.  
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Editorial Independence is concerned with whether the views of the funding body 
have influenced the content of the guideline and whether competing interests of guideline 
group members have been recorded and addressed.  
After completing assessments for the six domains, the instrument prompts the 
reviewer for an overall assessment of the guideline (using the same 1 to 7 Likert scale) 
and a categorical recommendation for use in clinical practice  (“yes,” “yes with 
modification,” or “no”). These two global assessments are based on the reviewer’s 
overall impression of the guideline and are not calculated from item or domain ratings. A 
full description of each quality domain, 23 items, and global assessments is provided in 
Appendix I.  
Sample data abstraction 
An example of an individual review of a clinical practice guideline using the 
AGREE II instrument is provided below (completed by reviewer AZ). Each of the 23 
items within the six domains is listed with its associated annotation and reason for rating.  
 
Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the 
Emergency Department Using the AGREE II Instrument 
1. Scope and Purpose 
1. The overall objective(s) of the guideline is (are) specifically described. 
Rating:  6 
Page 481, column 1. This clinical policy from ACEP addresses key issues for the 
diagnosis and management of adult psychiatric patients in the emergency 
department. A writing subcommittee conducted a systematic review of literature 
to derive evidence-based recommendations to answer the following clinical 
questions. The four clinical questions are clearly delineated. 
  
10
 
2. The health question(s) covered by the guideline is (are) specifically described. 
Rating:  7 
The guideline presents four "critical questions" (pages 483-487) in a very clear 
manner. Further, based on the definition provided and the discussion of each 
critical question, the context of the critical question relative to overall clinical 
practice is provided. 
 
3. The population (patients, public, etc.) to whom the guideline is meant to 
apply is specifically described. 
Rating:  7 
Page 483, column 1. Inclusion Criteria: This guideline applies to adult patients 
presenting to the ED with psychiatric symptoms.  
Critical Question 4 includes patients with delirium.  
Exclusion Criteria: This guideline is not intended to be used for pediatric patients. 
Also not intended for patients with delirium in regard to Critical Questions 1, 2, 3. 
 
2. Stakeholder Involvement 
4. The guideline development group includes individuals from all relevant 
professional groups. 
Rating: 5 
Page 482, column 1. This policy is a product of the ACEP Clinical Policy 
development process, including expert review. Expert review comments were 
received from emergency physicians, psychiatrists, members of the American 
Association for Emergency Psychiatry, the American Association of Community 
Psychiatrists, and ACEP's Medical Legal committee. Comments were received 
during a 60-day open-comment period, with notices of the comment period sent in 
an email to ACEP members, published in EM Today, and posted on the ACEP 
Web site. The responses were used to further refine and enhance the policy; 
however, they do not imply endorsement of this clinical policy. Lacks details of 
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how input from these institutions, members, or experts was used by the guideline 
development group. 
 
5. The views and preferences of the target population (patients, public, etc.) 
have been sought. 
Rating: 2 
No mention of seeking outside opinion (public, patient, etc.) was noted in the 
guideline. They do reference in the Intro (page 481) how ED are taking the 
weight of the substantial decline in mental health resource allocation for patients 
with mental health issues, but no proposal for how to get additional stakeholders 
involved. 
 
6. The target users of the guideline are clearly defined. 
Rating: 7 
Page 483, column 1. Scope of Application: This guideline is intended for 
physicians working in EDs. 
 
3. Rigor of Development 
7. Systematic methods were used to search for evidence. 
Rating: 6 
Page 482, column 1. This Clinical Policy was created after careful review and 
critical analysis of medical literature and was based on a systematic review of the 
literature. Searches of MEDLINE, MEDLINE InProcess, Scopus, Web of Science, 
and the Cochrane Database were performed. All searches were limited to 
English-language sources, adults, and human studies. Specific key words/phrases, 
years used in the searches, dates of searches, and study selection were identified 
under each critical question. In addition, relevant articles from the bibliographies 
of included studies and more recent articles identified by committee members and 
reviewers were included. 
 
8. The criteria for selecting the evidence are clearly described. 
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Rating: 6 
Page 482, column 1. As noted in Item 7. Additionally, the evidence was graded 
(page 482, column 1) and assigned a class (Class I, II, III) based on a 
predetermined process taking into account design and quality of study –
("Assessment of Classes of Evidence” – Appendix A, Appendix B and evidentiary 
table) for use in making the recommendation. The guideline describes the 
translation of evidence class for making the recommendation (Level A, B, C) 
(page 482, column 2). 
 
9. The strengths and limitations of the body of evidence are clearly described. 
Rating: 6 
Strengths and Limitations are mentioned. Examples: Page 482, column 1. All 
searches were limited to English-language sources, adults and human studies. 
Page 482, column 1. When literature was not available, consensus of emergency 
physicians was used. Page 482, column 2. There are certain circumstances in 
which the recommendation stemming from a body of evidence should not be rated 
as highly as the individual studies on which they are based. Page 483, column 1. 
This policy is not intended to be a complete manual on the diagnosis and 
management of adult psychiatric patients in the ED. Page 483, column 2. This 
policy is not intended to represent a legal standard of care for emergency 
physicians. Page 483, column 2. Recommendations not intended to represent the 
only diagnostic or management options. The guideline defines for the physician 
those strategies for which medical literature exist to provide support for answers 
to the critical questions addressed in this policy. Page 483, column 2. For 
potential benefits and harms of implementing the recommendations, see Appendix 
D. Page 486, column 2. This clinical policy demonstrates that there is no tool 
currently available that can be solely used to predict the risk of suicide among 
patient in the ED. 
 
10. The methods for formulating the recommendations are clearly described. 
Rating: 7 
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Methodology (page 482). Provides a detailed description of the methodology used, 
the review process, the citations by years, etc. There was a thorough assessment 
of the literature and the evidence was graded and assigned a grade (Class I, II, 
III) based on predetermined process taking into account design and quality of 
study (Appendix A and B, Evidentiary Table) for use in making the 
recommendation (Level A, B, C). For the Critical Questions (pages 483-487) 
there are logical discussions of the problems and literature leading up to a clear 
and concise "recommendation" for each of the four critical questions. 
 
11. The health benefits, side effects, and risks have been considered in 
formulating the recommendations. 
Rating: 6 
For potential benefits and harms of implementation the recommendation, the 
guideline provides Appendix D. This appendix uses the same format as the critical 
questions and recommendation, and provides a review of benefit/harm associated 
with the recommendations. More details could be provided. 
 
12. There is an explicit link between the recommendations and the supporting 
evidence. 
Rating: 7 
The four Critical Questions (pages 483-487) addressed in the guideline are 
clearly delineated and clinical practice recommendations are provided. Research 
supporting the recommendation is well described. Further, the recommendations 
are assigned a level (Level A, B, C) based on the strength of evidence (Class I, II, 
III) and expert opinion (Assessment of Classes of Evidence and Translation of 
Classes of Evidence to Recommendation Levels) (page 482, column 2). 
Additionally, inclusion of "future research" for each of the critical questions 
(page 484, column 1) provides additional insight into the current evidence 
supporting the clinical recommendation. 
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13. The guideline has been externally reviewed by experts prior to its 
publication. 
Rating: 5 
Page 482, column 1. This policy is a product of the ACEP Clinical Policy 
development process, including expert review. Expert review comments were 
received from emergency physicians, psychiatrists, members of the American 
Association for Emergency Psychiatry, the American Association of Community 
Psychiatrists, and ACEP's Medical Legal committee. Comments were received 
during a 60-day open-comment period, with notices of the comment period sent in 
an email to ACEP members, published in EM Today, and posted on the ACEP 
Web site. The responses were used to further refine and enhance this policy; 
however, they do not imply endorsement of this clinical policy. Lacks detailed 
description of reviewers, outcome and summary of key findings, and description 
of how/whether information was used in the guideline. 
 
14. A procedure for updating the guideline is provided. 
Rating: 5 
Page 482, column 1. Clinical policies are scheduled for review and considered 
for revision every 3 years, however, interim reviews are conducted when 
technology, methodology or the practice environment changes significantly. No 
definition/explanation of what "significantly" means. 
 
4. Clarity of Presentation 
15. The recommendations are specific and unambiguous. 
Rating: 5 
Critical Questions, pages 483-487. While the critical questions are clearly 
delineated, they are occasionally vague, and given the nature of the patients being 
treated (psychiatric patients) there are provided a range of management 
strategies. But in general, by grading the level of evidence (Class I, II, III) and 
using that grading in establishing the recommendation (Level A, B, C) the 
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guideline provides the ED physician with a level of confidence on how to interpret 
the recommendation, which is helpful. 
 
16. The different options for management of the condition or health issue are 
clearly presented. 
Rating: 5 
Each critical question (pages 483-487) is clearly defined, and research 
supporting the recommendation delineated. In these discussions, they provide 
clinical background and alternate choices. For example, Page 484, column 1. 
Existing literature indicates that routine or ancillary laboratory testing for 
psychiatric patients has little or no use in ED. It is likely that subsets of patients 
with higher rates of disease (e.g., elderly, immunosuppressed, new onset 
psychosis, substance abuse) may benefit from routine laboratory testing. Although 
urine toxicology screen has no benefit for management or disposition of the 
patient in the ED, it may be helpful to obtain an objective understanding of the 
patient’s potential substance abuse on transfer to a psychiatric facility. 
 
17. Key recommendations are easily identifiable. 
Rating: 7 
The critical questions addressed in the guideline (pages 483-487) are clearly 
delineated and clinical practice recommendations are provided. Further the 
recommendations are assigned a level (Level A, B, C) based on the strength of 
evidence (Class I, II, III) and expert opinion (page 482). 
 
5. Applicability 
18. The guideline describes facilitators and barriers to its application. 
Rating: 4 
Overall does not identify facilitators and barriers to application, but makes some 
comments about application. For example, Page 484, column 1: To expedite the 
care of patients, agreement between the ED and local psychiatric facilities 
regarding minimal laboratory testing for psychiatric clearance should be 
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mutually determined. Page 485, column 1: Given that many acutely psychiatric 
patients may not be able to cooperate with a comprehensive neurological 
examination, emergency physicians may have a lower threshold to obtain 
neuroimaging in these patients. Page 486, column 2: This clinical policy review 
demonstrates that there is no tool currently available that can be solely used to 
predict the risk of suicide among patients in the ED who have suicidal ideation. 
 
19. The guideline provides advice and/or tools on how the recommendations 
can be put into practice. 
Rating: 2 
The guideline does not address this explicitly. However, since the guideline is 
provided by ACEP to all members and published in Annals of Emergency 
Medicine, mere dissemination of the guideline promotes its use. The format of the 
guideline, by clearly identifying critical questions and then providing 
recommendations, facilitates use of the guideline. 
 
20. The potential resource implications of applying the recommendations have 
been considered. 
Rating: 2 
Resource implications for applying the guidelines were not explicitly addressed. 
However, in the evaluations and eventual recommendations (pages 483-487) it 
mentions trying to optimize testing and emergency department time and still 
provide optimal care. 
 
21. The guideline presents monitoring and/or auditing criteria. 
Rating: 2 
The guideline does not specifically address monitoring/auditing. 
 
6. Editorial Independence 
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22. The views of the funding body have not influenced the content of the 
guideline. 
Rating: 5 
Page 482, column 1. ACEP was the funding source for this ACEP clinical policy. 
The members of the ACEP policies committee could thus have an influence on this 
final guideline. This may be minor, but there is an opening for influence. 
 
23. Competing interests of guideline development group members have been 
recorded and addressed. 
Rating: 5 
Page 487, column 2. There were no relevant industry relationships disclosed by 
the subcommittee members for this topic. Relevant industry relationships are 
those relationships with companies associated with products or services that 
significantly impact the specific aspect of disease addressed in the critical 
questions. Would be more complete if all relationships the authors have both 
financially and academically were reported. 
 
Overall Assessment 
Overall Quality of This Guideline: 5/7 
Guideline Recommended for Use?  Yes. 
 
 Group appraisal process 
Data abstraction was designed to meet or exceed guidance of the AGREE II 
instrument developers. The AGREE II developers recommend a minimum of two 
appraisers and optimally four appraisers for stable estimates of CPG quality. In our study, 
all twenty ACEP Clinical Policies were reviewed by five appraisers (AZ, TT, GS, KC, 
and MJ). Prior to data abstraction, each appraiser completed a standardized online 
training module specifically for use of AGREE II (12, 34), and a group session was 
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conducted after reviewing the first three guidelines to ensure consistent use of definitions. 
All appraisals were performed independently between May 2017 and September 2017. 
Further, each appraiser was assigned a unique and random order to perform the data 
abstraction to minimize bias due to increased familiarity with the instrument over time. 
Data abstraction for underlying evidence and recommendations 
Each Clinical Policy contains clinical recommendations based on medical 
literature to address critical questions faced by emergency physicians. For each 
recommendation found in a Clinical Policy, we recorded the proportion of 
recommendations that were Level C (the weakest level of recommendation). Level C 
recommendations are based on evidence from Design Class III studies or expert 
consensus. We also recorded the proportion of references within each Clinical Policy that 
were graded as Design Class III evidence. Studies considered as Class III evidence are 
case series, case reports, and consensus or review papers.  
Outcomes  
The primary outcomes were AGREE II ratings for each item, each domain, 
Overall Assessment, and recommendation for use in clinical practice.  
Analysis 
Primary analysis 
For the primary descriptive analysis, domain and Overall Assessment ratings were 
standardized as a percentage according to the following formula recommended by 
AGREE II developers (32): 
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(Obtained score – Minimum possible score) / (Maximum possible score – Minimum 
possible score) x 100 
Ratings were calculated at the domain level and not at the item level. Using the 
example assessment above, the domain of Stakeholder Involvement is comprised of three 
items (items 4, 5, and 6) with item scores of 5, 2, and 7, respectively. The maximum 
score for this three-item domain is 21 (3 x 7) and the minimum score is 3 (3 x 1).  The 
obtained score from the above example was 14 (5 + 2 + 7). Thus, this domain’s 
standardized score was 61%, calculated by (14 - 3) / (21 – 3) x 100. 
The standardized score using this formula was determined for each domain and 
Overall Assessment for each reviewer. The standardized percentages from all five 
reviewers were then reported as the mean, standard deviation, coefficient of variation, 
and range.  
 Secondary analysis 
Secondary analyses were performed to further assess ACEP Clinical Policies. 
First, we examined whether AGREE II domain and Overall Assessment ratings changed 
over the ten-year span (2007-2017) that the Clinical Policies were published. We further 
evaluated AGREE II ratings before and after the ACEP Clinical Policy methodology was 
updated in September 2015 using t-tests for each domain and Overall Assessment. 
Second, we evaluated for any relationship between each domain rating and Overall 
Assessment rating by calculating correlation coefficients between each domain and the 
Overall Assessment rating. Third, we examined the association between AGREE II 
ratings and the strengths of the CPGs’ underlying evidence and recommendations. We 
report correlation coefficients between AGREE II Overall Assessment ratings and 1) the 
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proportion of Class III evidence within an ACEP Clinical Policy and 2) the proportion of 
Level C recommendations within an ACEP Clinical Policy. These measures have been 
previously utilized to describe the strength of emergency medicine clinical practice 
guidelines (6).   
In addition, to examine inter-rater reliability between the five appraisers, we 
calculated intra-class coefficients (ICC) for each of the six quality domains. This 
approach is consistent with prior studies utilizing the AGREE II instrument. For all 
analysis, we considered alpha equal to or less than 0.05 to be statistically significant and 
we accounted for multiple comparisons using the Bonferroni correction where 
appropriate (35). Data analysis was performed using R statistical software (version 3.4.2). 
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Results 
 
Data set description 
This study included twenty clinical practice guidelines published by ACEP 
between April 2007 and November 2017. Of all included guidelines, 13 were published 
prior to methodological updates in September 2015 and seven (35%, ACEP 1- 6 and 
ACEP 20) were published after the update (Table I).  
Results of primary analysis 
The mean results from the standardized scores of all five reviewers are provided 
in Table II.  The results for the primary analysis rated by this author (AZ) using the 
standardized scoring formula can be found in Appendix II.  
Of the six AGREE II domains, Scope and Purpose had the highest mean rating 
and the lowest variability (mean rating 90%, coefficient of variation (CV) of 0.03, range 
84 – 96%). Applicability had the lowest mean rating and highest variability (mean rating 
35%, CV of 0.16, range 37 - 77%). The four remaining domains, from highest to lowest 
rating, were Rigor of Development (mean rating 78%, CV of 0.03, range 73 – 83%), 
Clarity of Presentation (mean rating 75%, CV of 0.07, range 59 – 82%), Editorial 
Independence (mean rating 68%, CV of 0.13, range 37 – 77%), and Stakeholder 
Involvement (mean rating 53%, CV of 0.08, range 46 – 63%).  
For the Overall Assessment, the mean rating for all twenty CPGs from the five 
appraisers was 69% with CV of 0.13 and a range from 50% to 83% (Table II). The three 
Clinical Policies with the highest mean Overall Assessments ratings were “Neuroimaging 
and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting” (83%), 
“Emergency Department Management of Patients Needing Reperfusion Therapy for an 
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ST-Segment Elevation Acute Myocardial Infarction” (80%), and "Clinical Policy for 
Well-Appearing Infants and Children Younger Than 2 Years of Age Presenting to the 
Emergency Department With Fever” (80%). The three Clinical Policies with the lowest 
mean Overall Assessment ratings were “Critical Issues in the Evaluation and 
Management of Emergency Department Patients With Suspected Appendicitis” (50%), 
“Critical Issues in the Evaluation and Management of Adult Patients in the Emergency 
Department with Asymptomatic Elevated Blood Pressure” (50%), and “Clinical Issues in 
the Prescribing of Opioids for Adult Patients in the Emergency Department” (53%).   
Regarding whether the five appraisers recommended these guidelines for clinical 
use, the vast majority of responses were “yes” or “yes with modifications” (Table III). 
There were, however, “no” responses for Clinical Policies on asymptomatic elevated 
blood pressure (two “no” recommendations), prescribing opioids for adult patients (two 
“no” recommendations), suspected appendicitis (one “no” recommendation), and acute 
carbon monoxide poisoning (one “no” recommendation).  These four clinical policies 
also had the four lowest mean Overall Assessment ratings of all Clinical Policies in this 
study (50%, 53%, 50% and 63%, respectively). There was low inter-rater reliability with 
ICC values ranging from 0.01 to 0.07. 
Results of secondary analysis 
There was no significant relationship between Overall Assessment rating and date 
of CPG publication (Figure 1). Further, there was no significant improvement in the 
Overall Assessment ratings or in any of the six domains after updates to ACEP guideline 
development process in September 2015 (Table IV).  
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Of the six domains, Rigor of Development and Clarity of Presentation had the 
strongest association with the Overall Assessment rating (R = 0.70, p < 0.001; R = 0.77, p 
< 0.0001, respectively) (Table V). The other four domains’ ratings were not strongly 
associated with Overall Assessment rating (R: 0.01 - 0.51). 
The listing of recommendation level, class of evidence, and Overall Assessment 
rating for each Clinical Policy is shown in Table VIa and VIb. No significant correlation 
was evident between Overall Assessment and either the proportion of Level C 
recommendations (R= 0.06, p = 0.96) (Figure 2a) or proportion of Class III evidence (R= 
0.01, p = 0.79) (Figure 2b). 
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Discussion 
 
Study summary 
Overall, ACEP Clinical Policies rated highly based on the validated AGREE II 
instrument of CPG quality. There was, however, variability in the quality of ACEP 
Clinical Policies based on AGREE II domains, with strengths primarily in Scope and 
Purpose, Rigor of Development, and Clarity of Presentation; weakness in Applicability; 
and mixed results in Stakeholder Involvement and Editorial Independence. There were no 
significant improvements in any domain or Overall Assessment ratings over time. The 
domains of Rigor of Development and Clarity of Presentation were most strongly 
associated with Overall Assessment ratings. We did not find that AGREE II ratings were 
sensitive to the CPG’s strength of underlying evidence. These findings carry important 
implications for emergency medicine clinical guideline developers, the broader clinical 
practice guideline community, and physicians using these guidelines to provide 
emergency care.  
Discussion of primary results 
ACEP Clinical Policies showed highest quality in Scope and Purpose. Compared 
to prior published research, our finding that this domain scored highest (mean rating 
90%) and varied least (CV 3.1%) is not surprising. For example, studies utilizing the 
AGREE II instrument to evaluate CPGs for hepatocellular carcinoma (37), spinal 
conditions (23), and intracranial aneurysms (36) similarly reported Scope and Purpose as 
the highest scoring domain. The quality elements of the Scope of Purpose domain 
(objectives, clinical questions, and target population) are inherently addressed in ACEP 
Clinical Policies due to ACEP’s standardized and formulaic guideline development 
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process centered on clear clinical questions.  
ACEP Clinical Policies also showed strengths in Rigor of Development (mean 
rating 78%) and Clarity of Presentation (mean rating 75%). The aim of the Rigor of 
Development domain is to evaluate whether the methods and guideline development 
process are thorough and transparent, specifically in searching for evidence, assessing the 
quality of evidence, and formulating recommendations. Prior research has shown that 
many guidelines in other specialties lack explanation of the quality of underlying 
evidence or strength of recommendations (36). ACEP Clinical Policies clearly present the 
level of each recommendation and provide explanation of the CPG’s underlying evidence. 
This is a strength that demonstrates appropriate methodological transparency in ACEP’s 
guideline development process. However, while ACEP Clinical Policies thoroughly 
describe the process of searching for evidence, they could be improved with a more direct 
explanation or specific examples of how the evidence is linked to each specific 
recommendation. For Clarity of Presentation, we found that ACEP Clinical Policies use 
clear language, are formatted logically, provide specific recommendations, and consider 
alternative options for management. Overall, high mean ratings in Scope and Purpose, 
Rigor of Development, and Clarity of Presentation indicate strong technical quality and 
clear delivery of information in ACEP Clinical Policies.  
The lowest scoring domain across ACEP Clinical Policies was Applicability. The 
quality elements of Applicability include facilitators and barriers to CPG application, 
resource implications of the recommendations, and monitoring or audit criteria. Other 
studies have shown similar weakness in the Applicability domain, and thus it is 
reasonable that this domain had both the lowest score (mean rating 35%) and highest 
  
26
variability (CV 0.16). For example, Wang et al. (37) evaluated 40 guidelines related to 
liver cancer and found that most guidelines failed to address tools required for facilitating 
guideline implementation, resulting in an average Applicability domain rating of 16% 
using the AGREE II instrument. Low scores in Applicability could reflect a belief that 
guideline development and guideline implementation are separate activities. Guideline 
developers may feel that the organizational barriers and cost implications are better 
discussed among local administrators who can make more individualized decisions based 
on local settings or institutional priorities. This seems especially true in the practice of 
emergency medicine, which is greatly affected by practice location, available resources, 
and patient demographics. Therefore, statements about appropriate implementation of 
recommendations and resource implications are difficult to make universally, so the low 
mean rating and high variability for this domain across the 20 CPGs in this study were 
expected. The Applicability domain ratings for these ACEP Clinical Policies could be 
improved with clearer monitoring criteria and discussion of both the resource 
implications and barriers to guideline implementation.  Given the resources and time 
required to develop these guidelines, it is understandable that frequent revisions are 
infeasible; however, regular updates in a less formal manner, such as an official online 
forum or mobile application could be utilized to disseminate new influential evidence that 
becomes available. This approach has been taken by developers of Guideline Central 
(available at https://www.guidelinecentral.com/mobile-and-web-apps/), a digital resource 
and mobile application that provides official recommendations from various respected 
medical associations and is frequently updated to reflect the latest content.  
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There were two domains that received mixed ratings: Stakeholder Involvement 
(mean rating 53%) and Editorial Independence (mean rating 69%). While ACEP Clinical 
Policies are developed in collaboration with individuals from multiple relevant 
professional groups, they do not explicitly mention seeking the views and preferences of 
the target population (38). This is a common weakness among CPGs in the U.S.: 
Armstrong and Bloom (38) recently reviewed 101 guideline development organizations 
and reported that only 8% consistently require patient and public involvement. Given the 
increasing emphasis on patient partnership in research and policy making, U.S. guideline 
development organizations should look to examples such as the National Institute for 
Clinical Excellence in the U.K. for models on including patient representation in 
guideline development (5, 38). Editorial Independence assesses whether the CPG’s 
development was influenced by funding sources or interests of the authors to determine 
whether recommendations are based on the best-available evidence alone or affected by 
those with conflicts of interest. Editorial independence has been a long-standing source of 
controversy for CPGs in several specialties. In 2004, new cholesterol guidelines greatly 
expanded the number of people recommended for treatment, and yet the vast majority of 
guideline authors were found to have relationships with manufacturers of cholesterol 
lowering drugs (39). Another survey found that most chairs and co-chairs of clinical 
policy committees had financial conflicts of interest (21). The risks of poor editorial 
independence are numerous. Guidelines disseminated by respected organizations can be 
utilized to create institutional protocols, develop quality measures, inform insurance 
coverage decisions, and influence the selection of medications on drug formularies (17): 
the quality and reliability of all of these are threatened by biased guidelines. Further, 
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CPGs can be viewed as reliable authority in malpractice lawsuits, and this may place 
pressure on physicians to follow guideline recommendations even if they have concern 
about industry influence over guideline development. Our results for the Editorial 
Independence domain (mean rating 69%) indicate that ACEP Clinical Policies could 
improve in this area but are relatively strong in this domain compared to other guidelines 
(7, 19, 20, 24-27). To improve the strength of Editorial Independence, more explicit and 
thorough disclosure about both financial and intellectual conflicts of interest among 
guideline developers should be included. Further, explanation should be provided about 
how these conflicts of interest were managed and accounted for (i.e., whether certain 
competing interests excluded members from specific aspects of guideline development).  
In addition to the domain level ratings, the mean Overall Assessment rating for all 
20 Clinical Policies was quite high at 69%. Of note, however, the Overall Assessment 
component is a new addition since the original AGREE instrument and warrants 
consideration of its nuances. Unlike the 23 appraisal items within the six domains that 
have detailed criteria to guide appraisers, the Overall Assessment does not include 
specific directions, and is the most subjective component of the AGREE II instrument. 
This dichotomy of including both formulaic and subjective elements may be confusing 
for users and those interpreting the instrument’s output. AGREE II developers could offer 
advice about how to arrive at an Overall Assessment rating, perhaps with suggestions for 
weighing the six domains or by providing other relevant criteria. If, however, AGREE II 
developers believe it is important to maintain some area for flexibility and subjectivity 
that transcends specific criteria, it should at least be made clear to those interpreting 
AGREE II scores that Overall Assessment ratings are subjective and distinct from the 
  
29
item-defined domain ratings. Overall, these authors believe there is value to this 
subjective component of the AGREE II instrument, and our results indicate the global 
strength of the ACEP Clinical Policy development methodology. 
Most ACEP Clinical Policies were recommended for clinical use by our five 
appraisers, which supports our opinion that ACEP Clinical Policies are of high quality. 
There were, however, four guidelines that some appraisers did not recommend for 
clinical use. It is noteworthy that the guidelines that received any “no” responses for 
recommendation for clinical use also had the lowest Overall Assessment ratings, 
indicating agreement between these two modes of assessment. 
Our results extend the findings of two other recent studies that utilized the 
AGREE II instrument to evaluate individual ACEP Clinical Policies, revealing similar 
strengths and weaknesses.  First, Pak et al. (40) assessed three guidelines on management 
of hypertension, including one published by ACEP. Compared to our results for that 
ACEP Clinical Policy, Pak et al. reported a similar average domain rating (67% vs. our 
result of 65%) and similar rankings for domain scores, with Scope and Purpose and Rigor 
of Development scoring highest and Applicability scoring lowest. The similar average 
domain rating and domain ranking suggest good agreement and consistency between two 
different groups of appraisers evaluating the same ACEP Clinical Policy.  
Second, Patel et al. (27) evaluated 24 CPGs related to management of traumatic 
brain injury, including one ACEP Clinical Policy. They reported mean domain and 
Overall Assessment ratings similar to those in our study, again suggesting consistency 
and reliability with the AGREE II instrument between two different appraisal groups. An 
older study, Tavender et al. (41), utilized the original AGREE instrument in 2010 to 
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evaluate the same ACEP Clinical Policy on traumatic brain injury. Tavender et al.’s 
ratings were consistently lower than those in our study, but the order of domain 
performance, from highest to lowest, was identical to ours, suggesting that Tavender et 
al.’s appraisers were consistently more strict but identified similar areas of strength and 
weakness in the Clinical Policy.   
Inter-rater reliability 
Our results of low intraclass coefficients suggest poor inter-rater reliability. The 
ICC in this study can be explained by the low variance of ratings in comparison to the 
total possible variance of a seven-item scale. While a modestly higher ICC may be 
achieved with a larger number of guidelines or reviewers, the effect of a larger sample 
size on the ICC is not likely to be substantial as this study already exceeded the 
recommended number of reviewers by the AGREE II developers.  Given the ICC’s 
sensitivity to low score variability between reviewers in each domain, an alternative 
approach to measuring agreement between reviewers may be more appropriate for 
examining broad consistency between reviewers (such as whether reviewers consistently 
rate each domain above or below an average as opposed to a measure of scale).  
Discussion of secondary analysis 
We conducted several secondary analyses to explore trends and underlying causes 
of the variation in AGREE II domain and Overall Assessment ratings.  
 Trends in AGREE II ratings over time 
We did not find that domain or Overall Assessment ratings improved over the 
prior decade or after recent methodological updates. As discussed previously, concern 
about conflict of interest in the 2013 tPA Clinical Policy generated substantial 
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controversy and sparked ACEP’s methodological updates that became effective in 2015. 
However, our study using the AGREE II instrument did not find significant improvement 
in the editorial independence of ACEP’s Clinical Policy development process since these 
updates.  
Relationships between domain ratings and overall assessment ratings 
To better understand how appraisers may arrive at Overall Assessment ratings, we 
examined whether particular domain ratings were correlated with Overall Assessment 
ratings. Our findings that Rigor of Development and Clarity of Presentation were most 
strongly associated with Overall Assessment do not imply that these two domains are 
predictive of the Overall Assessment rating, but rather suggest that strong performance 
on these two domains may be influential on the appraiser’s overall impression of the 
CPG’s quality. Similarly, Hoffmann-Esser et al. (42) evaluated various aspects of the 
AGREE II Overall Assessment ratings in 1453 guidelines and found that Rigor of 
Development had the strongest correlation with Overall Assessment rating. This likely 
reflects that clinicians highly value the thoroughness of the literature search and final 
structure of a guideline in evaluating overall CPG quality. 
Strength of underlying evidence and level of recommendations 
We found that AGREE II ratings were not sensitive to the proportion of 
underlying Class III evidence or proportion of Level C recommendations within the 
CPGs, and this is consistent with the design of the AGREE II instrument. While AGREE 
II evaluates whether the guideline reports the quality of underlying evidence and presents 
the recommendations clearly, the instrument does not consider the strength of evidence or 
recommendations in formulating its quality assessment of the CPG. In other words, the 
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AGREE II criteria are blind to the quality of evidence supporting the guideline. This is 
both a strength and weakness of the AGREE II instrument. One benefit is that the 
AGREE II instrument specifically examines elements performed by, and in the control of, 
guideline authors, and the instrument is less sensitive to factors beyond authors’ control 
(i.e., amount of available literature or strength of scientific evidence). However, this 
attribute is a weakness because AGREE II ratings do not necessarily indicate whether the 
recommendations within a CPG can be followed reliably. It is possible that a CPG can 
score very high on most criteria of AGREE II and yet have no reliable benefit in clinical 
practice.  
Implications for AGREE II instrument developers and users  
Overall, our appraisers found the AGREE II instrument to be well structured, user 
friendly, thorough, and useful in assessing guideline quality. Notable strengths include its 
informative online training module, detailed instructions with examples for scoring each 
item, logical and comprehensive structure of items and domains, and an easy-to-use 
online interface. A weakness of this instrument for those interested in implementing 
recommendations into practice is its inability to evaluate the quality of evidence or 
reliability of the CPG’s recommendations. This, however, is advantageous for guideline 
authors who strictly seek to know if their development process is rigorous and transparent. 
The current AGREE II reflects methodological processes and not necessarily content, and 
so high AGREE II scores reflect the quality of reporting more than quality of evidence or 
content.  Including criteria that considers the strength of underlying evidence would 
create a more comprehensive instrument that could provide physicians with more 
confidence in implementing CPGs with high AGREE II ratings.  
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Finally, while the AGREE II instrument has been thoroughly validated and shown 
to be reliable, evidence is still lacking about whether high AGREE II ratings translate to 
substantial benefits for guidelines’ stakeholders, which include institutions, guideline 
developers, administrators, physicians, and patients. For example, in the previously 
discussed Pak et al. study on guidelines for hypertension, ACEP’s Clinical Policy had 
higher AGREE II ratings than the CPG published by the European Society of 
Hypertension (ESH). Despite the ACEP Clinical Policy’s relatively strong performance 
according to AGREE II domain ratings, the authors of that study did not recommend 
ACEP’s guideline for clinical use, while they did recommend the lower scoring CPG by 
ESH. Those authors justified this by explaining that the ACEP Clinical Policy did not 
address management of hypertensive emergency, indicating that AGREE II ratings and 
clinical usefulness are not necessarily related. Future research should explore how 
utilization of the AGREE II instrument can affect the implementation of CPGs, 
knowledge translation, and clinical outcomes. 
Implications for ACEP Clinical Policies development and use 
Our study has identified specific strengths and weaknesses of ACEP Clinical 
Policies.  Even though addressing all issues of applicability may be infeasible or an 
inefficient utilization of limited ACEP resources, some additional consideration of 
resource implications, barriers or facilitators for implementation, and monitoring or audit 
criteria would improve these Clinical Policies within the current scope of development. 
Future guidelines should at least inform users of the need to consider applicability issues 
when implementing guideline recommendations. ACEP Clinical Policies could be also 
improved with broader stakeholder involvement that includes representation from 
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patients or target populations and more thorough disclosure about both financial and 
intellectual conflicts of interest among guideline developers.  
 
Limitations 
 
There are limitations of this project that warrant discussion. While this study has 
focused on guideline appraisal using the AGREE II instrument, it is worthwhile to 
compare this instrument with the IOM’s standards of guideline trustworthiness in 
“Clinical Practice Guidelines We Can Trust” (5). While some consider the IOM’s 
standards to be more comprehensive than AGREE II (16, 17), the disadvantages to sole 
utilization of the IOM’s standards are that they are not structured into a validated 
instrument for easy use and they offer only an inflexible all-or-nothing definition of 
guideline trustworthiness. The AGREE II instrument covers similar content as the IOM’s 
standards in a more user-friendly structure and more realistically manages partial 
adherence to its criteria and, thus, is best suited for the aims of this study.  
Use of the AGREE II instrument also has potential for bias as appraisers become 
more familiar with the instrument. Ratings performed initially may be affected by a 
reviewer’s unfamiliarity with the instrument or scale. Later, reviewers may improve their 
consistency, be influenced by their prior ratings, or alter their interpretation of the rating 
scale. Thus, we aimed to minimize this potential bias by assigning each appraiser a 
unique randomized order to perform appraisals. In addition, all appraisers were from the 
same academic center, and this may result in an institutional bias. One analytic limitation 
of this study approach is the risk of committing type 1 error when performing multiple 
comparisons; thus, we accounted for this by implementing the Bonferroni correction 
where appropriate. Based on the ICC calculation, there was low inter-rater reliability in 
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this study, and this was likely due to a low variance of ratings in comparison to the total 
possible variance of a seven-item scale. Future work should explore alternative statistical 
methods for assessing the consistency of responses between reviewers. Finally, our 
analysis was limited to clinical practice guidelines developed by ACEP and did not 
include any guidelines published by other specialty societies, in other countries, or in 
other languages; therefore, many emergency care guidelines housed within the 
documents and writing of other specialties or organizations are absent from this work.  
 
Conclusions 
 
ACEP Clinical Policies demonstrate strengths and weaknesses based on validated 
criteria provided by the AGREE II instrument. Guideline quality did not improve over 
time or after ACEP methodological updates in 2015 and is not related to the quality of 
underlying evidence. ACEP Clinical Policies can be improved by including patient 
representation in the guideline development process, increasing editorial independence 
and transparency, and addressing factors that influence the application of these guidelines 
in clinical practice.     
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Figures & Tables 
 
Figure 1.  Comparison of Publication Year and Overall Assessment Rating 
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Figure 2. Comparison of Overall Assessment Rating and Either Proportion of Level C Recommendations (2A) or Proportion 
of Class III Evidence (2B) 
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Table I.   American College of Emergency Physicians – Current Clinical Policies 
ID Title 
Publication 
Date 
ACEP-1 Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department Apr 2017 
ACEP-2 Critical Issues in the Initial Evaluation and Management of Patients Presenting to the Emergency Department in Early Pregnancy Feb 2017 
ACEP-3 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Carbon 
Monoxide Poisoning 
Jan 2017 
ACEP-4 Critical Issues in the Evaluation of Adult Patients with Suspected Transient Ischemic Attack in the Emergency Department Sep 2016 
ACEP-5 
Clinical Policy for Well-Appearing Infants and Children Younger Than 2 Years of Age Presenting to the Emergency Department 
With Fever 
May 2016 
ACEP-6 Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department Sep 2015 
ACEP-7 
Critical Issues in the Evaluation and Management of Adult Patients With Suspected Acute Nontraumatic Thoracic Aortic 
Dissection 
Jan 2015 
ACEP-8 Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Seizures Apr 2014 
ACEP-9 Procedural Sedation and Analgesia in the Emergency Department Feb 2014 
ACEP-10 
Critical Issues in the Evaluation and Management of Adult Patients in the Emergency Department with Asymptomatic Elevated 
Blood Pressure 
Jul 2013 
ACEP-11 Clinical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department Oct 2012 
ACEP-12 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Suspected 
Pulmonary Embolism 
Jun 2011 
ACEP-13 Critical Issues in the Evaluation of Adult Patients Presenting to the Emergency Department With Acute Blunt Abdominal Trauma Apr 2011 
ACEP-14 Critical Issues in the Evaluation and Management of Emergency Department Patients With Suspected Appendicitis Jan 2010 
ACEP-15 
Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Community-Acquired 
Pneumonia 
Nov 2009 
ACEP-16 Neuroimaging and Decision making in Adult Mild Traumatic Brain Injury in the Acute Setting Dec 2008 
ACEP-17 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute 
Headache 
Oct 2008 
ACEP-18 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart 
Failure Syndromes 
May 2007 
ACEP-19 Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Syncope Apr 2007 
ACEP-20 
Emergency Department Management of Patients Needing Reperfusion Therapy for an ST-Segment Elevation Acute Myocardial 
Infarction 
Nov 2017 
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Table II.  Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy 
Guideline Title ID 
Scope 
and 
Purpose 
Stakeholder 
Involvement 
Rigor of 
Development 
Clarity of 
Presentation 
Applicability 
Editorial 
Independence 
 
Overall 
Assessment 
Critical Issues in the Diagnosis 
and Management of the Adult 
Psychiatric Patient in the 
Emergency Department 
ACEP-
1 
84% 52% 78% 73% 42% 75% 
 
70% 
Critical Issues in the Initial 
Evaluation and Management of 
Patients Presenting to the 
Emergency Department in Early 
Pregnancy 
ACEP-
2 
88% 54% 80% 74% 32% 72% 
 
70% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Acute Carbon Monoxide 
Poisoning 
ACEP-
3 
86% 51% 76% 78% 32% 77% 
 
63% 
Critical Issues in the Evaluation 
of Adult Patients with Suspected 
Transient Ischemic Attack in the 
Emergency Department 
ACEP-
4 
93% 48% 81% 76% 46% 72% 
 
77% 
Clinical Policy for Well-
Appearing Infants and Children 
Younger Than 2 Years of Age 
Presenting to the Emergency 
Department With Fever 
ACEP-
5 
96% 52% 81% 82% 38% 75% 
 
80% 
Use of Intravenous Tissue 
Plasminogen Activator for the 
Management of Acute Ischemic 
Stroke in the Emergency 
Department 
ACEP-
6 
92% 46% 77% 72% 36% 73% 
 
73% 
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Table II.  Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy 
Guideline Title ID 
Scope 
and 
Purpose 
Stakeholder 
Involvement 
Rigor of 
Development 
Clarity of 
Presentation 
Applicability 
Editorial 
Independence 
 
Overall 
Assessment 
Critical Issues in the Evaluation 
and Management of Adult 
Patients With Suspected Acute 
Nontraumatic Thoracic Aortic 
Dissection 
ACEP-
7 
91% 51% 80% 73% 36% 77% 
 
70% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Seizures 
ACEP-
8 
90% 51% 78% 76% 27% 62% 
 
67% 
Procedural Sedation and 
Analgesia in the Emergency 
Department 
ACEP-
9 
92% 58% 82% 77% 35% 62% 
 
70% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients in the Emergency 
Department with Asymptomatic 
Elevated Blood Pressure 
ACEP-
10 
90% 49% 74% 69% 33% 77% 
 
50% 
Clinical Issues in the Prescribing 
of Opioids for Adult Patients in 
the Emergency Department 
ACEP-
11 
90% 63% 75% 72% 36% 67% 
 
53% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department With 
Suspected Pulmonary Embolism 
ACEP-
12 
91% 51% 77% 79% 33% 73% 
 
73% 
Critical Issues in the Evaluation 
of Adult Patients Presenting to 
the Emergency Department With 
Acute Blunt Abdominal Trauma 
ACEP-
13 
88% 52% 77% 78% 32% 68% 
 
70% 
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Table II.  Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy 
Guideline Title ID 
Scope 
and 
Purpose 
Stakeholder 
Involvement 
Rigor of 
Development 
Clarity of 
Presentation 
Applicability 
Editorial 
Independence 
 
Overall 
Assessment 
Critical Issues in the Evaluation 
and Management of Emergency 
Department Patients With 
Suspected Appendicitis 
ACEP-
14 
87% 51% 73% 59% 29% 65% 
 
50% 
Critical Issues in the 
Management of Adult Patients 
Presenting to the Emergency 
Department With Community-
Acquired Pneumonia 
ACEP-
15 
92% 56% 77% 76% 37% 68% 
 
70% 
Neuroimaging and 
Decisionmaking in Adult Mild 
Traumatic Brain Injury in the 
Acute Setting 
ACEP-
16 
93% 58% 78% 82% 44% 72% 
 
83% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department With 
Acute Headache 
ACEP-
17 
89% 52% 75% 80% 36% 63% 
 
67% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Acute Heart Failure Syndromes 
ACEP-
18 
91% 52% 75% 77% 27% 58% 
 
73% 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Syncope 
ACEP-
19 
90% 53% 76% 73% 25% 37% 
 
70% 
Emergency Department 
Management of Patients 
Needing Reperfusion Therapy 
ACEP-
20 
91% 60% 82% 81% 43% 68% 
 
80% 
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Table II.  Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy 
Guideline Title ID 
Scope 
and 
Purpose 
Stakeholder 
Involvement 
Rigor of 
Development 
Clarity of 
Presentation 
Applicability 
Editorial 
Independence 
 
Overall 
Assessment 
for an ST-Segment Elevation 
Acute Myocardial Infarction 
Mean ± SD 90 ± 2.8 53 ± 4.2 78 ± 2.7 75 ± 5.2 35 ± 5.7 68 ± 9.2 
 
69 ± 9.1 
Coefficient of Variation (CV) 0.03 0.08 0.03 0.07 0.16 0.14 
 
0.13 
Range 84 - 96 46 - 63 73 - 82 59 - 82 25 - 46 37 - 77  50 – 83 
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Table III.  Appraiser Recommendation for Clinical Policy Use and Overall Assessment 
Guideline 
ID 
Guideline Title 
Five Appraisers  
Overall 
Assessment Yes 
Yes With 
Modifications 
No 
 
ACEP-1 
Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in 
the Emergency Department 
3 2 0 
 
70% 
ACEP-2 
Critical Issues in the Initial Evaluation and Management of Patients Presenting to 
the Emergency Department in Early Pregnancy 
3 2 0 
 
70% 
ACEP-3 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department with Acute Carbon Monoxide Poisoning 
3 1 1 
 
63% 
ACEP-4 
Critical Issues in the Evaluation of Adult Patients with Suspected Transient 
Ischemic Attack in the Emergency Department 
4 1 0 
 
77% 
ACEP-5 
Clinical Policy for Well-Appearing Infants and Children Younger Than 2 Years of 
Age Presenting to the Emergency Department With Fever 
4 1 0 
 
80% 
ACEP-6 
Use of Intravenous Tissue Plasminogen Activator for the Management of Acute 
Ischemic Stroke in the Emergency Department 
2 3 0 
 
73% 
ACEP-7 
Critical Issues in the Evaluation and Management of Adult Patients With Suspected 
Acute Nontraumatic Thoracic Aortic Dissection 
4 1 0 
 
70% 
ACEP-8 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department with Seizures 
3 2 0 
 
67% 
ACEP-9 Procedural Sedation and Analgesia in the Emergency Department 4 1 0 
 
70% 
ACEP-10 
Critical Issues in the Evaluation and Management of Adult Patients in the 
Emergency Department with Asymptomatic Elevated Blood Pressure 
2 1 2 
 
50% 
ACEP-11 
Clinical Issues in the Prescribing of Opioids for Adult Patients in the Emergency 
Department 
1 2 2 
 
53% 
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Table III.  Appraiser Recommendation for Clinical Policy Use and Overall Assessment 
Guideline 
ID 
Guideline Title 
Five Appraisers  
Overall 
Assessment Yes 
Yes With 
Modifications 
No 
 
ACEP-12 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department With Suspected Pulmonary Embolism 
4 1 0 
 
73% 
ACEP-13 
Critical Issues in the Evaluation of Adult Patients Presenting to the Emergency 
Department With Acute Blunt Abdominal Trauma 
4 1 0 
 
70% 
ACEP-14 
Critical Issues in the Evaluation and Management of Emergency Department 
Patients With Suspected Appendicitis 
1 3 1 
 
50% 
ACEP-15 
Critical Issues in the Management of Adult Patients Presenting to the Emergency 
Department With Community-Acquired Pneumonia 
4 1 0 
 
70% 
ACEP-16 
Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the 
Acute Setting 
4 1 0 
 
83% 
ACEP-17 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department With Acute Headache 
2 3 0 
 
67% 
ACEP-18 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department with Acute Heart Failure Syndromes 
4 1 0 
 
73% 
ACEP-19 
Critical Issues in the Evaluation and Management of Adult Patients Presenting to 
the Emergency Department with Syncope 
4 1 0 
 
70% 
ACEP-20 
Emergency Department Management of Patients Needing Reperfusion Therapy for 
an ST-Segment Elevation Acute Myocardial Infarction 
4 1 0 
 
80% 
Five appraisers of 20 Guidelines 
(100 recommendations) 
64/100 
(64%) 
30/100 
(30%) 
6/100 
(6%) 
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Table IV. Domain Ratings Before and After ACEP Clinical Policy Methodology Updates 
AGREE II Domain Pre-Sept 2015 Rating Post-Sept 2015 Rating p-valueA 
Scope and Purpose 90% 90% p = 0.67 
Stakeholder Involvement 53% 53% p = 0.94 
Rigor of Development 77% 80% p = 0.02 
Clarity of Presentation 74% 77% p = 0.18 
Applicability 33% 38% p = 0.09 
Editorial Independence 66% 73% p = 0.03 
AStatistical significance was defined as p < 0.008 using the Bonferroni correction to account for 
multiple comparisons 
 
 
  
  
49
 
 
Table V.  Correlation Table Comparing the Six AGREE II Domains and Overall Assessment 
 Variable 
Scope 
and 
Purpose 
Stakeholder 
Involvement 
Rigor of 
Development 
Clarity of 
Presentation 
Applicability 
Editorial 
Independence 
Overall 
Assessment 
Scope and Purpose 1 
      
Stakeholder 
Involvement 
0.09 1 
     
Rigor of Development 0.43 0.20 1 
    
Clarity of Presentation 0.42 0.25 0.52 1 
   
Applicability 0.28 0.21 0.53 0.36 1 
  
Editorial 
Independence 
0.01 0.19 0.21 0.08 0.54 1 
 
Overall Assessment 0.51 0.05 
0.70 
A(p = 0.001) 
0.77 
A(p= 0.0001) 
0.46 0.01 1 
AStatistical significance was defined as p < 0.007 using the Bonferroni correction to account for multiple comparisons. 
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Table VI(a).  Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating  
Policy 
ID 
Policy Title 
Date of 
Publication 
Number of 
Recommendations 
Recommendation Level Class of Evidence 
  
Overall 
Assessment Level 
A 
Level 
B 
Level 
C 
Class 
I 
Class 
II 
Class 
III 
ACEP-
20 
Emergency Department 
Management of Patients Needing 
Reperfusion Therapy for Acute 
ST-Segment Elevation 
Myocardial Infarction  
Nov 2017 4 0 2 2 0 2 7 
  
80% 
ACEP-
1 
Critical Issues in the Diagnosis 
and Management of the Adult 
Psychiatric Patient in the 
Emergency Department 
Apr 2017 4 0 0 4 0 0 6 
  
70% 
ACEP-
2 
Critical Issues in the Initial 
Evaluation and Management of 
Patients Presenting to the 
Emergency Department in Early 
Pregnancy 
Feb 2017 3 0 2 1 0 10 10 
  
63% 
ACEP-
3 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Acute Carbon Monoxide 
Poisoning 
Jan 2017 3 0 3 0 0 6 8 
  
77% 
ACEP-
4 
Critical Issues in the Evaluation of 
Adult Patients with Suspected 
Transient Ischemic Attack in the 
Emergency Department 
Sep 2016 4 0 2 2 0 18 45 
  
80% 
ACEP-
5 
Clinical Policy for Well-
Appearing Infants and Children 
Younger Than 2 Years of Age 
Presenting to the Emergency 
Department With Fever 
May 2016 6 0 2 4 0 3 19 
  
73% 
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Table VI(a).  Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating  
Policy 
ID 
Policy Title 
Date of 
Publication 
Number of 
Recommendations 
Recommendation Level Class of Evidence 
  
Overall 
Assessment Level 
A 
Level 
B 
Level 
C 
Class 
I 
Class 
II 
Class 
III 
ACEP-
6 
Use of Intravenous Tissue 
Plasminogen Activator for the 
Management of Acute Ischemic 
Stroke in the Emergency 
Department 
Sep 2015 2 0 2 2 1 6 71 
 
73% 
ACEP-
7 
Critical Issues in the Evaluation 
and Management of Adult 
Patients With Suspected Acute 
Nontraumatic Thoracic Aortic 
Dissection 
Jan 2015 6 0 2 4 2 3 23 
 
70% 
ACEP-
8 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Seizures 
April 2014 6 1 1 4 1 3 32 
 
67% 
ACEP-
9 
Procedural Sedation and 
Analgesia in the Emergency 
Department 
Feb 2014 6 1 3 2 2 10 16 
 
70% 
ACEP-
10 
Critical Issues in the Evaluation 
and Management of Adult 
Patients in the Emergency 
Department with Asymptomatic 
Elevated Blood Pressure 
Jul 2013 2 0 0 2 0 2 4 
 
50% 
ACEP-
11 
Clinical Issues in the Prescribing 
of Opioids for Adult Patients in 
the Emergency Department 
Oct 2012 5 0 1 4 1 4 15 
 
53% 
ACEP-
12 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department With 
Suspected Pulmonary Embolism 
Jun 2011 10 1 5 4 9 38 75 
 
73% 
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Table VI(a).  Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating  
Policy 
ID 
Policy Title 
Date of 
Publication 
Number of 
Recommendations 
Recommendation Level Class of Evidence 
  
Overall 
Assessment Level 
A 
Level 
B 
Level 
C 
Class 
I 
Class 
II 
Class 
III 
ACEP-
13 
Critical Issues in the Evaluation of 
Adult Patients Presenting to the 
Emergency Department With 
Acute Blunt Abdominal Trauma 
Apr 2011 6 0 3 3 1 7 7 
 
70% 
ACEP-
14 
Critical Issues in the Evaluation 
and Management of Emergency 
Department Patients With 
Suspected Appendicitis 
Jan 2010 4 0 3 1 9 21 35 
 
50% 
ACEP-
15 
Critical Issues in the Management 
of Adult Patients Presenting to the 
Emergency Department With 
Community-Acquired Pneumonia 
Nov 2009 4 0 2 2 0 10 20 
 
70% 
ACEP-
16 
Neuroimaging and 
Decisionmaking in Adult Mild 
Traumatic Brain Injury in the 
Acute Setting 
Dec 2008 5 1 2 2 4 15 24 
 
83% 
ACEP-
17 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department With 
Acute Headache 
Oct 2008 6 0 3 3 1 10 32 
 
67% 
ACEP-
18 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Acute Heart Failure Syndromes 
May 2007 7 0 4 3 5 34 31 
 
73% 
ACEP-
19 
Critical Issues in the Evaluation 
and Management of Adult 
Patients Presenting to the 
Emergency Department with 
Syncope 
Apr 2007 5 2 2 1 4 8 10 
 
70% 
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Table VI (b). Description of CPG Level Recommendation and Classification of Literature/EvidenceA 
Level A Recommendation:  
Generally accepted principles for patient 
care that reflect a high degree of clinical 
certainty (e.g., based on evidence from 1 or 
more Class of Evidence I or multiple Class 
of Evidence II studies) 
Level B Recommendation: 
Recommendation for patient care that may 
identify a particular strategy or range of 
strategies that reflect moderate clinical 
certainty (e.g., based on evidence from 1 or 
more Class of Evidence II studies or strong 
consensus of Class of Evidence III studies) 
Level C Recommendations:  
Recommendations for patient care 
that are based on evidence from 
Class of Evidence III studies or in 
the absence of any adequate 
published literature, based on expert 
consensus 
 
Literature/Evidence Classification Schema 
Design 
Class 
Therapy Diagnosis Prognosis 
I 
Randomized, controlled trial or 
meta-analysis of randomized trials 
Prospective cohort using a criterion standard 
or meta-analysis of prospective studies 
Population prospective cohort or 
meta-analysis of prospective studies 
II Nonrandomized trial Retrospective observational Retrospective cohort.  Case control 
III Case series Case series Case series 
AThe recommendation levels and Design Class (I, II,III) are from ACEP Clinical Policy Development Process 
https://www.acep.org/Clinical---Practice-Management/ACEP-Clinical-Policies-Development-
Process/#sm.00000nl048nlvdoawtf22kfngb0xo 
The Design Class descriptions are found in Appendix A of the Clinical Policies 
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Appendix 
 
Appendix I: The AGREE II Instrument 
 
Domain 1. Scope and Purpose is concerned with the overall aim of the guideline, the specific health questions and the target population (items 1-
3). 
1) Objectives(s) – The overall objectives and guidelines is (are) specifically described 
2) Question(s) – The health question(s) is (are) specifically described 
3) Population – (patients, public, etc) to whom the guideline is meant to apply is specifically described 
 
Domain 2. Stakeholder Involvement focuses on the extent to which the guideline was developed by the appropriate stakeholders and represents 
the views of its intended users (items 4 -6). 
4) Guidelines Group – the guideline development group includes individuals from all relevant professional groups 
5) Patient Preferences – The view / preferences of the target population (patients, public, etc) have been sought 
6) Target – The target users of the guideline are clearly defined 
 
Domain 3. Rigor of Development relates to the process used to gather and synthesize the evidence and the methods to formulate and update the 
recommendations (items 7-14). 
7) Systematic Methods – Systematic methods were used to search for evidence 
8) Selection Criteria – The criteria for selecting the evidence are clearly described 
9) Strength and Limitations – The strengths and limitations of the body of evidence are clearly described 
10) Method of Recommendations – The methods for formulating the recommendations are clearly described 
11) Benefits, Side Effects and Risks – These aspects have been considered in formulating the recommendations  
12) Evidence Link – There is an explicit link between the recommendations and the supporting evidence 
13) External Review – The guideline has been externally reviewed by experts prior to its publication 
14) Update Procedures – A procedure for updating the guideline is provided 
 
Domain 4. Clarity of Presentation deals with the language, structure, and format of the guideline (items 15-17). 
15) Recommendation Specific - The recommendations are specific and unambiguous 
16) Options for Management – Different options for management of the condition/health issue are clearly presented  
17) Recommendations identifiable – Key recommendation are easily identifiable 
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Domain 5. Applicability pertains to the likely barriers and facilitators to implementation, strategies to improve uptake, and resource implications 
of applying the guideline (items 18-21). 
18) Facilitators and Barriers – The guideline describes facilitators and barriers to its application 
19) Tools – The guideline provides advice and/or tools on how the recommendation can be put into practice 
20) Resource Implications – Potential resource implications of applying the recommendation have been considered 
21) Monitoring/Audit Criteria – The guideline presents monitoring and/or auditing criteria. 
 
Domain 6. Editorial Independence is concerned with the formulation of recommendations not being unduly biased with competing interests 
(items 22-23). 
22) Funding Body – The views of the funding body have not influenced the content of the guideline 
23) Competing Interests – Competing interests of guideline group members have been recorded and addressed.  
 
Overall Assessment includes the rating of the 
• The overall quality of the guideline (1-7 scale) 
• Whether the guideline would be recommended for use in practice (yes, yes with modification, or no) 
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Appendix II 
 
AGREE II Domains and Overall Assessment Ratings by AZ 
Clinical Policy 
ID 
Scope and 
Purpose 
(21)A 
Stake Holder 
Involvement 
(21) 
Rigor of 
Development 
(56) 
Clarity of 
Presentation 
(21) 
Applicability 
(28) 
Editorial 
Independence 
(14) 
Overall 
Quality 
(7) 
Critical Issues in the Diagnosis and 
Management of the Adult Psychiatric 
Patient in the Emergency Department 
1 
20 
(94%)B 
14 
(61%) 
48 
(83%) 
17 
(78%) 
10 
(25%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Initial Evaluation 
and Management of Patients Presenting 
to the Emergency Department in Early 
Pregnancy 
2 
20 
(94%) 
14 
(61%) 
48 
(83%) 
17 
(78%) 
7 
(13%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients 
Presenting to the Emergency 
Department with Acute Carbon 
Monoxide Poisoning 
3 
20 
(94%) 
13 
(56%) 
48 
(83%) 
17 
(78%) 
7 
(13%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation of Adult 
Patients with Suspected Transient 
Ischemic Attack in the Emergency 
Department 
4 
20 
(94%) 
12 
(50%) 
48 
(83%) 
17 
(78%) 
9 
(21%) 
10 
(67%) 
5 
(67%) 
Clinical Policy for Well-Appearing 
Infants and Children Younger Than 2 
Years of Age Presenting to the 
Emergency Department With Fever 
5 
20 
(94%) 
14 
(61%) 
48 
(83%) 
17 
(78%) 
8 
(17%) 
10 
(67%) 
5 
(67%) 
Use of Intravenous Tissue Plasminogen 
Activator for the Management of Acute 
Ischemic Stroke in the Emergency 
Department 
6 
20 
(94%) 
11 
(44%) 
45 
(77%) 
17 
(78%) 
9 
(21%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients With 
Suspected Acute Nontraumatic Thoracic 
Aortic Dissection 
7 
20 
(94%) 
13 
(56%) 
48 
(83%) 
17 
(78%) 
7 
(13%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation and 8 20 14 46 17 8 10 5 
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AGREE II Domains and Overall Assessment Ratings by AZ 
Clinical Policy 
ID 
Scope and 
Purpose 
(21)A 
Stake Holder 
Involvement 
(21) 
Rigor of 
Development 
(56) 
Clarity of 
Presentation 
(21) 
Applicability 
(28) 
Editorial 
Independence 
(14) 
Overall 
Quality 
(7) 
Management of Adult Patients 
Presenting to the Emergency 
Department with Seizures 
(94%) (61%) (83%) (78%) (17%) (67%) (67%) 
Procedural Sedation and Analgesia in 
the Emergency Department 
9 
20 
(94%) 
14 
(61%) 
46 
(79%) 
17 
(78%) 
8 
(17%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients in the 
Emergency Department with 
Asymptomatic Elevated Blood Pressure 
10 
20 
(94%) 
13 
(56%) 
45 
(77%) 
17 
(78%) 
8 
(17%) 
10 
(67%) 
5 
(67%) 
Clinical Issues in the Prescribing of 
Opioids for Adult Patients in the 
Emergency Department 
11 
20 
(94%) 
19 
(89% 
46 
(79%) 
17 
(78%) 
8 
(17%) 
12 
(83%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients 
Presenting to the Emergency 
Department With Suspected Pulmonary 
Embolism 
12 
20 
(94%) 
13 
(56%) 
46 
(79%) 
17 
(78%) 
6 
(8%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation of Adult 
Patients Presenting to the Emergency 
Department With Acute Blunt 
Abdominal Trauma 
13 
20 
(94%) 
13 
(56%) 
46 
(79%) 
17 
(78%) 
6 
(8%) 
10 
(67%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Emergency Department 
Patients With Suspected Appendicitis 
14 
20 
(94%) 
13 
(56%) 
46 
(79%) 
17 
(78%) 
7 
(13%) 
8 
(50%) 
5 
(67%) 
Critical Issues in the Management of 
Adult Patients Presenting to the 
Emergency Department With 
Community-Acquired Pneumonia 
15 
20 
(94%) 
15 
(67%) 
46 
(79%) 
17 
(78%) 
7 
(13%) 
8 
(50%) 
5 
(67%) 
Neuroimaging and Decision making in 
Adult Mild Traumatic Brain Injury in 
the Acute Setting 
16 
20 
(94%) 
13 
(56%) 
44 
(75%) 
17 
(78%) 
7 
(13%) 
12 
(83%) 
5 
(67%) 
  
58
AGREE II Domains and Overall Assessment Ratings by AZ 
Clinical Policy 
ID 
Scope and 
Purpose 
(21)A 
Stake Holder 
Involvement 
(21) 
Rigor of 
Development 
(56) 
Clarity of 
Presentation 
(21) 
Applicability 
(28) 
Editorial 
Independence 
(14) 
Overall 
Quality 
(7) 
Critical Issues in the Evaluation and 
Management of Adult Patients 
Presenting to the Emergency 
Department With Acute Headache 
17 
20 
(94%) 
13 
(56%) 
46 
(79%) 
18 
(83%) 
7 
(13%) 
8 
(50%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients 
Presenting to the Emergency 
Department with Acute Heart Failure 
Syndromes 
18 
20 
(94%) 
13 
(56%) 
46 
(79%) 
17 
(78%) 
6 
(8%) 
8 
(50%) 
5 
(67%) 
Critical Issues in the Evaluation and 
Management of Adult Patients 
Presenting to the Emergency 
Department with Syncope 
19 
20 
(94%) 
13 
(56%) 
46 
(79%) 
17 
(78%) 
5 
(4%) 
4 
(17%) 
5 
(67%) 
Emergency Department Management of 
Patients Needing Reperfusion Therapy 
for an ST-Segment Elevation Acute 
Myocardial Infarction 
20 
20 
(94%) 
14 
(61%) 
46 
(79%) 
17 
(78%) 
10 
(25%) 
10 
(67%) 
5 
(67%) 
Range 94 – 94% 50 – 89% 77 – 83% 78 – 83% 4 – 25% 17 – 83% 67 – 67% 
AMaximum Score for each AGREE II domain is in parentheses 
BEach domain and overall assessment score is standardized as a percentage according to the following formula recommended by AGREE II developers (AGREE 
Next Steps Consortium, 2009, The AGREE II Instrument (Electronic version). http://www.agreetrust.org.): 
(Obtained score – Minimum possible score) / (Maximum possible score – Minimum possible score) x 100 
 
